4/A: Daewoong Pharmaceutical Invests $10 Million in AEON Biopharma via Convertible Note

Daewoong Pharmaceutical Co., Ltd. acquired a $10 million senior secured convertible note in AEON Biopharma, Inc. on April 12, 2024, which is convertible into Class A common stock under certain conditions.

Summary

• Daewoong Pharmaceutical Co., Ltd. (DWP) acquired a $10 million senior secured convertible note in AEON Biopharma, Inc. (AEON) on April 12, 2024.
• The note accrues interest at an annual rate of 15.79% and matures three years from the funding date (April 12, 2027), unless earlier repurchased, converted, or redeemed.
• The note is convertible into shares of AEON's Class A common stock, subject to certain conditions and limitations.
• If AEON completes a qualified financing of at least $30 million through the sale of common stock or securities convertible into common stock, the note will automatically convert into common stock.
• The conversion price will be based on 1.3 times the quotient of the principal amount of the note plus accrued interest divided by the per share price of the common stock in the qualified financing, provided that the per share price is at least $1.00.
• Daewoong Co., Ltd. indirectly owns shares of Daewoong Pharmaceutical Co., Ltd. and has voting and dispositive power over those shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The investment is a positive sign for AEON, but the high interest rate and dependence on future financing introduce some uncertainty.

Positives

• AEON Biopharma receives a $10 million investment from Daewoong Pharmaceutical.
• The convertible note structure allows for potential equity upside for Daewoong Pharmaceutical.
• The automatic conversion feature is triggered by a significant financing event, potentially indicating positive momentum for AEON.
• The 15.79% interest rate provides a steady return for Daewoong Pharmaceutical while awaiting potential conversion.

Negatives

• The high interest rate of 15.79% on the convertible note could be a burden for AEON Biopharma.
• The conversion is contingent on AEON achieving a qualified financing of at least $30 million, which may not occur.
• The conversion terms are complex and dependent on the share price in a future financing round.

Risks

• AEON Biopharma may not be able to secure a qualified financing of at least $30 million.
• The value of AEON's common stock could decline, reducing the potential return on the convertible note.
• The terms of the convertible note could be dilutive to existing shareholders if the note is converted.
• There are customary events of default associated with the note.

Future Outlook

The future depends on AEON Biopharma's ability to secure a qualified financing of at least $30 million, which would trigger the automatic conversion of the note into common stock. The value of the investment for Daewoong Pharmaceutical is tied to the performance of AEON's stock and its ability to attract further investment.

Industry Context

This investment reflects continued interest in the biopharmaceutical sector, with companies like Daewoong Pharmaceutical seeking strategic investments in promising firms like AEON Biopharma. Convertible notes are a common financing tool in the biotech industry, allowing investors to participate in potential upside while providing capital to companies with uncertain near-term revenue streams.

Comparison to Industry Standards

• Convertible notes are a common financing tool in the biotech industry, allowing investors to participate in potential upside while providing capital to companies with uncertain near-term revenue streams.
• The 15.79% interest rate is relatively high, suggesting that AEON Biopharma may have had limited access to capital at lower rates.
• Similar companies such as Biohaven Pharmaceutical Holding Company Ltd. have used convertible notes to raise capital.
• The $30 million qualified financing threshold is a significant milestone for AEON Biopharma, and achieving this would be a positive signal to the market.

Stakeholder Impact

• Shareholders of AEON Biopharma may experience dilution if the convertible note is converted into common stock.
• Employees of AEON Biopharma may benefit from the increased financial stability provided by the investment.
• Customers and suppliers of AEON Biopharma may see improved service and reliability as a result of the investment.
• Creditors of AEON Biopharma may be more confident in the company's ability to meet its obligations.

Next Steps

• AEON Biopharma needs to execute its business plan and attract further investment to achieve the qualified financing threshold.
• Daewoong Pharmaceutical will monitor AEON's progress and assess the potential for conversion of the note into common stock.

Key Dates

Keywords

convertible note, AEON Biopharma, Daewoong Pharmaceutical, investment, financing, common stock, qualified financing